Dr. Martens (LON:DOCS) Insider Ije Nwokori Acquires 112,500 Shares

Dr. Martens plc (LON:DOCS) insider Ije Nwokori bought 112,500 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of GBX 76 per share, with a total value of £85,500.

Ije Nwokori also recently made the following trade(s):

• On Thursday, June 11th, Ije Nwokori bought 202 shares of Dr. Martens stock. The stock was bought at an average price of GBX 74 per share, for a total transaction of £149.48.
• On Wednesday, May 13th, Ije Nwokori purchased 233 shares of Dr. Martens stock. The shares were bought at an average cost of GBX 64 per share, for a total transaction of £149.12.
• On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The stock was sold at an average price of GBX 66, for a total value of £134,673.66.
• On Tuesday, April 14th, Ije Nwokori acquired 232 shares of Dr. Martens stock. The stock was purchased at an average cost of GBX 65 per share, with a total value of £150.80.

Dr. Martens Stock Up 0.6%

Dr. Martens stock traded up GBX 0.40 during midday trading on Tuesday, hitting GBX 72.50. The stock had a trading volume of 377,685 shares, compared to its average volume of 8,721,683. The business has a fifty day moving average price of GBX 67.35 and a 200 day moving average price of GBX 69.69. Dr. Martens plc has a 12 month low of GBX 59.15 and a 12 month high of GBX 100.87. The stock has a market cap of £693.89 million, a P/E ratio of 30.21, a P/E/G ratio of 6.40 and a beta of 0.25. The company has a current ratio of 2.61, a quick ratio of 1.13 and a debt-to-equity ratio of 108.27.

Dr. Martens (LON:DOCS) last issued its earnings results on Tuesday, May 19th. The company reported GBX 4.20 EPS for the quarter. The company had revenue of £764.90 million during the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%. Research analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analyst Weigh In

DOCS has been the subject of several recent research reports. Berenberg Bank lowered their target price on shares of Dr. Martens from GBX 114 to GBX 110 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Royal Bank Of Canada restated a “sector perform” rating and issued a GBX 100 price target on shares of Dr. Martens in a research report on Tuesday, June 2nd. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Dr. Martens has a consensus rating of “Moderate Buy” and a consensus target price of GBX 105.

Dr. Martens Company Profile

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.